ArticleIndian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
Incidence and Determinants of Post-Coronavirus Disease Syndrome by Disease Severity: An Ambispective Cohort Study from a Tertiary Care Hospital in Puducherry.
Article in Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-coronavirus disease 2019 (COVID-19) condition, or long COVID, persists beyond the acute phase, impacting quality of life. This study estimated the incidence and determinants of post-COVID syndrome (PCS) in Puducherry, India. Methods: This ambispective cohort study from May to December 2022 included 1162 adults with COVID-19. Participants were stratified by disease severity (moderate/severe and mild) based on clinical parameters during acute illness. We conducted follow-ups at 1, 3, 6, and 12 months. PCS was defined as having ≥two of five common symptoms (fatigue, joint/muscle pain, breathing difficulty, loss of smell/taste, or sleep problems). Relative risks (RR) and 95% confidence intervals (CI) were estimated using binomial regression with a Poisson link, adjusting for socio-demographic and clinical factors. Results: Incidence of PCS was consistently higher in the moderate/severe group. At 1, 3, 6, and 12 months, incidence was 65.6%, 37.7%, 24.4%, and 34.4% for moderate/severe cases, and 24.3%, 11.0%, 7.1%, and 16.9% for mild cases, respectively. Moderate/severe cases had significantly higher RR of 2.70 at 1 month (95% CI: 2.31-3.15), 3.42 at 3 months (95% CI: 2.65-4.40), 3.46 at 6 months (95% CI: 2.49-4.80), and 2.04 at 12 months (95% CI: 1.65-2.52), all Conclusion: Moderate/severe COVID-19 severity and specific socio-demographic and clinical factors were associated with an elevated risk of PCS. Early identification and targeted follow-up are recommended to mitigate long-term impacts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.